ClinicaliQ Trial Snapshot
- Rademikibart Add-on Treatment of an Acute Asthma Exacerbation (Seabreeze STAT Asthma) — Recruiting • Phase II • Respiratory / COPD / Asthma • NCT06940141.
- This is a Phase 2, randomized, multicenter study in adult and adolescent participants with asthma and type 2 inflammation.
- Sponsor: Connect Biopharm LLC.
Verify eligibility, endpoints and current status on the original source registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a Phase 2, randomized, multicenter study in adult and adolescent participants with asthma and type 2 inflammation
Eligibility Snapshot
- : * Physician-diagnosed asthma with duration of ≥12 months. * Currently receiving treatment with low, medium, to high dose ICS in combination with at least 1 additional asthma controller medication. * Must have experienced at least 1 asthma exacerbation requiring the use of systemic corticosteroids. * For participants in a stable condition, must have a documented historical peripheral blood eosinophil count of ≥250 cells/μL and/or FeNO ≥ 25 ppb. * Current acute asthma exacerbation requiring an urgent healthcare visit for treatment. * Peripheral blood eosinophil count of ≥300 cells/µL as part of the assessment of an index acute asthma exacerbation. * Requires systemic corticosteroid as SoC in the urgent healthcare setting to treat the current acute asthma exacerbation. * FEV1 ≥30% predicted.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.